Rory Nealon

1 result

Amryt Pharma, which focuses on developing treatments to help patients with rare and orphan diseases, expects its listing on New York’s Nasdaq to complete in July. Photograph: iStock

Amryt Pharma, the Dublin-based biopharmaceutical company, almost doubled the total remuneration of its boss last year to $1.6 million (€1.42 million) (...)